SCHEDULE: Paul Anthony Jacobs Discloses 6.6% Stake in Nuo Therapeutics

Paul Anthony Jacobs has reported beneficial ownership of 6.6% of Nuo Therapeutics, Inc.'s common stock, including exercisable warrants.

Summary

• Paul Anthony Jacobs, a U.S. citizen, has filed an Amendment No. 2 to Schedule 13G regarding his beneficial ownership in Nuo Therapeutics, Inc.
• The filing reports beneficial ownership of 3,183,500 shares of Nuo Therapeutics, Inc. Common Stock.
• This ownership represents 6.6% of the company's outstanding common stock.
• The total shares beneficially owned include 43,500 shares of Common Stock issuable upon the exercise of immediately exercisable warrants.
• Paul Anthony Jacobs holds sole voting power and sole dispositive power over all 3,183,500 shares.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant individual stake (6.6%) often implies a degree of confidence from the investor, though it is a routine disclosure without performance details.

Positives

• A significant individual investor, Paul Anthony Jacobs, holds a 6.6% stake, which can signal confidence in the company's future prospects.
• The beneficial ownership includes shares from immediately exercisable warrants, indicating a direct investment interest.

Industry Context

StockSavvy.ai notes that this filing is a standard disclosure of beneficial ownership by an individual investor and does not directly reflect broader industry trends or competitive dynamics, but rather a specific investment position within Nuo Therapeutics.

Stakeholder Impact

• Shareholders may view the significant stake held by Paul Anthony Jacobs as a positive indicator of investor confidence in Nuo Therapeutics.

Key Dates

Recommendation

The filing indicates a significant beneficial ownership stake by an individual, Paul Anthony Jacobs, which can be interpreted as a sign of confidence. However, as a Schedule 13G, it does not provide financial performance data or strategic updates to warrant a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, acknowledging the investor's position without further operational insights.

Keywords

Nuo Therapeutics, Paul Anthony Jacobs, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Shareholder Stake